A Phase IIa Study to Evaluate Pulmazole in Patients with Asthma and Allergic Bronchopulmonary Aspergillosis (ABPA)

Trial Profile

A Phase IIa Study to Evaluate Pulmazole in Patients with Asthma and Allergic Bronchopulmonary Aspergillosis (ABPA)

Planning
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs Itraconazole (Primary)
  • Indications Allergic bronchopulmonary aspergillosis
  • Focus Therapeutic Use
  • Sponsors Pulmatrix
  • Most Recent Events

    • 23 Jul 2018 According to Pulmatrix media release, this study will be utilizing a design informed by the expertise of the Clinical Advisory Board of Pulmatrix.
    • 16 Mar 2018 New trial record
    • 13 Mar 2018 According to a Pulmatrix media release, this trial is expected to begin in Q4 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top